Tech Company Financing Transactions

Checkmate Pharmaceuticals Funding Round

On 6/17/2017, Checkmate Pharmaceuticals announced $27 million in Series B funding from F-Prime Capital, Sofinnova Ventures and venBio.

Transaction Overview

Announced On
6/17/2017
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series B
Investors

F-Prime Capital (Lead Investor) (Ben Auspitz)

Sofinnova Ventures

venBio

Proceeds Purpose
Proceeds from the financing will be used to further advance clinical development of CMP-001, a first-in-class CpG-A oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9), and which is currently being studied in a Phase 1b trial in combination with pembrolizumab in primary refractory melanoma patients who have either progressed on or failed to respond to anti-PD-1 therapy.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Email Address
Overview
Checkmate Pharma is developing a new approach for cancer immunotherapy, by specifically activating the immune system to recognize and kill tumor cells throughout the body, without harming normal tissues.
Profile
Checkmate Pharmaceuticals LinkedIn Company Profile
Social Media
Checkmate Pharmaceuticals Company Twitter Account
Company News
Checkmate Pharmaceuticals News
Facebook
Checkmate Pharmaceuticals on Facebook
YouTube
Checkmate Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Barry Labinger
  Barry Labinger LinkedIn Profile  Barry Labinger Twitter Account  Barry Labinger News  Barry Labinger on Facebook
Chief Financial Officer
Jon Lieber
  Jon Lieber LinkedIn Profile  Jon Lieber Twitter Account  Jon Lieber News  Jon Lieber on Facebook
Chief Medical Officer
James Wooldridge
  James Wooldridge LinkedIn Profile  James Wooldridge Twitter Account  James Wooldridge News  James Wooldridge on Facebook
Chief Operating Officer
Karen Brennan
  Karen Brennan LinkedIn Profile  Karen Brennan Twitter Account  Karen Brennan News  Karen Brennan on Facebook
Chief Scientific Officer
Art Krieg
  Art Krieg LinkedIn Profile  Art Krieg Twitter Account  Art Krieg News  Art Krieg on Facebook
VP - Bus. Development
Kleem Chaudhary
  Kleem Chaudhary LinkedIn Profile  Kleem Chaudhary Twitter Account  Kleem Chaudhary News  Kleem Chaudhary on Facebook
VP - General Counsel
Chuck Yon
  Chuck Yon LinkedIn Profile  Chuck Yon Twitter Account  Chuck Yon News  Chuck Yon on Facebook
VP - Operations
Lisa White
  Lisa White LinkedIn Profile  Lisa White Twitter Account  Lisa White News  Lisa White on Facebook
VP - Regulatory Affairs
Chris French
  Chris French LinkedIn Profile  Chris French Twitter Account  Chris French News  Chris French on Facebook
VP - Regulatory Affairs
Steven Hamburger
  Steven Hamburger LinkedIn Profile  Steven Hamburger Twitter Account  Steven Hamburger News  Steven Hamburger on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/17/2017: Atrium LTS venture capital transaction
Next: 6/17/2017: Guazi.com venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary